argenx N.V.

General Information
Business:

(Note: Not an IPO: “Our ordinary shares are listed on Euronext Brussels under the symbol “ARGX.”) since 2014.”

We are a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing our suite of technologies, we are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 66
Founded: 2008
Contact Information
Address Willemstraat 5, 4811 AH, Breda, the Netherlands
Phone Number +31 763 030 488
Web Address http://www.argen-x.com
View Prospectus: argenx N.V.
Financial Information
Market Cap
Revenues $15.8 mil (last 12 months)
Net Income $-22.9 mil (last 12 months)
IPO Profile
Symbol ARGX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $74.8 mil
Manager / Joint Managers Cowen and Company/ Piper Jaffray
CO-Managers JMP Securities? Wedbush PacGrow
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change